When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says.

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible ... at the White House on Feb. 26 - Image: Andrew Harnik (Getty Images) Three ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... announcement had a similar effect, with the stock up just over 5% at the time of writing.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 2.08 ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Hims & Hers Health (HIMS) stock enjoyed ... sales of its GLP-1 injection, a compounded version of Semaglutide. The FDA allowed such alternatives due to a shortage of the original drug until ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...